Latest updates for Bempidoic Acid

Fresh curated links around bempidoic acid are collected here so marketers can spot useful updates and turn timely ideas into posts faster.

Recent items include:

  • FDA approves AstraZeneca’s new kind of hypertension drug
  • Baxfendy approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension
  • FDA Approves AstraZeneca Drug With New Approach to Lowering High Blood Pressure

Post angles to try

Share the most useful takeaway for your audience.
Turn one article into a quick practical checklist.
Ask your audience how this shift affects their work.
Turn angles into scheduled posts

Fresh articles and ideas

Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.

biopharmadive.com /1 week ago

FDA approves AstraZeneca’s new kind of hypertension drug

Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” that should ultimately generate $5 billion or more in an...

Read source
webwire.com /1 week ago

Baxfendy approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension

AstraZeneca's Baxfendy (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with oth...

Read source
medcitynews.com /1 week ago

FDA Approves AstraZeneca Drug With New Approach to Lowering High Blood Pressure

AstraZeneca’s Baxfendy is the first FDA-approved drug in a new class of medicines called aldosterone synthase inhibitors. The new mechanism of action is important for patients and...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.

Sources covering Bempidoic Acid

rssfeeds.webwire.com

Recent coverage from public sources
Public source

medcitynews.com

Recent coverage from public sources
Public source

biopharmadive.com

Recent coverage from public sources
Public source